Updated Data from Part A of Verastem Oncology's RAMP 201 Tri

Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer


Clinically Meaningful Response Rates and Manageable Safety and... | May 25, 2023

Related Keywords

London , City Of , United Kingdom , Berlin , Germany , United States , American , Racheln Grisham , Susana Banerjee , European Network Of Gynaecological Oncological Trial , Exchange Commission , Company Annual Report On Form , National Cancer Institute , Gynecologic Oncology Group , European Society Of Gynaecological Oncology , Foundation Inc , Partners Program , Amgen , European Network For Gynaecological Oncological Trial , Chugai Pharmaceutical Co Ltd , Drug Administration , Secura Bio Inc , Raf And Mek Program , Institute Of Cancer Research , American Society Of Clinical Oncology Annual Meeting , Team Leader In Women Cancers , Verastem Oncology , American Society , Clinical Oncology Annual Meeting , Breakthrough Therapy Designation , Selection Phase , Expansion Phase , Consultant Medical Oncologist , Royal Marsden , Team Leader , Cancer Research , Defactinib Combination , Section Head , Ovarian Cancer , Westchester Gynecologic Medical Oncology , Memorial Sloan Kettering Cancer Center , Breakthrough Therapy , Low Grade Serous Ovarian Cancer , European Network , Gynaecological Oncological Trial , European Society , Gynaecological Oncology , Secura Bio , Annual Report , Verastem , Nc Stock Exchange , News , Information , Press Release , Data , Build , N , Breakthrough , Therapy , Resignation , F , The , Combination , Avutometinib , End , Defactinib , Serous , Ovarian , Meaningful , Response , Rates , Unmanageable , Afety Vstm Us92337c1045 ,